2228. Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Patients with Diabetes: Outcomes from a Global Phase 3 Study of Delafloxacin (DLX)

BACKGROUND: Delafloxacin (DLX) is an IV/oral anionic fluoroquinolone with no QT restrictions. It is approved for the treatment of serious skin infections including those due to MRSA and Gram-negative pathogens. A Phase 3 trial of patients with CABP was recently completed comparing DLX to moxifloxaci...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaidashev, Igor, Nitu, Mimi, Popescu, Monica, Lawrence, Laura, Quintas, Megan, Li, Yang, Cammarata, Sue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809807/
http://dx.doi.org/10.1093/ofid/ofz360.1906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809807/
http://dx.doi.org/10.1093/ofid/ofz360.1906

Ejemplares similares